Clinical trial NCT06666075: Digital Reminiscence Therapy for Alzheimer's in Institutionalized People
Official title: Psychological and Mental Health of Institutionalized People Over 60 Years of Age With Alzheimer's: Effects of a Digital and Interactive Reminiscence Program.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Alzheimer Disease
Lead sponsor: University of Jaén
Sponsor class: OTHER
First posted: 2024-10-30
Enrollment: 72
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Digital reminiscence therapy (DRT) is an innovative intervention designed to enhance the psychological health of institutionalized seniors with Alzheimer's disease. This approach utilizes digital tools to facilitate the sharing of personal memories and experiences, fostering social interaction and emotional engagement. By combining technology with therapeutic reminiscence techniques, DRT aims to stimulate cognitive function and improve mood, potentially alleviating symptoms of anxiety and depression commonly observed in this population.

Research indicates that reminiscence therapy can lead to improvements in quality of life and overall well-being for individuals with dementia. The interactive nature of digital platforms encourages participation and allows caregivers to customize content based on the individual's preferences and history. As such, DRT not only serves to strengthen the connections between seniors and their pasts but also enhances their current social interactions, promoting a sense of identity and belonging. Overall, DRT represents a promising avenue for addressing the psychological needs of older adults with Alzheimer's in institutional settings, highlighting the potential benefits of integrating technology into therapeutic practices.


Eligibility criteria: Inclusion Criteria:

* People over 60 years of age.
* Confirmed diagnosis of mild or moderate Alzheimer's, where the patient still retains a certain degree of autobiographical memory.
* People institutionalized in a geriatric care center or similar.
* Level of cognitive impairment that allows understanding and basic interaction with digital tools.
* Approval and signature of informed consent by the participant or his/her legal representative, demonstrating agreement to participate in the study.
* Availability or access to devices (tablets or computers) provided by the study program or the care center.

Exclusion Criteria:

* Diagnosis of other neurological or psychiatric conditions (such as vascular dementia, Parkinson's, or psychotic disorders) that may significantly interfere with the program's results.
* Patients in advanced stages of Alzheimer's with severe limitations in remembering autobiographical events or interacting with digital devices.
* Vision, hearing, or fine motor problems that prevent the use of electronic devices in an appropriate manner, without the possibility of adaptation or assistance.
* Individuals or legal representatives who are unable or unwilling to give informed consent.
* Behaviors that may put the participant, staff, or other residents at risk when carrying out program activities.

Primary outcomes:
measure: The Quality of Life in Alzheimer's Disease (QoL-AD)
timeFrame: Up to twelve weeks
measure: Mini-Mental State Examination (MMSE)
timeFrame: Up to twelve weeks
measure: Montreal Cognitive Assessment (MoCA)
timeFrame: Up to twelve weeks
measure: Trail Making Test (TMT)
timeFrame: Up to twelve weeks
measure: Isaacs test
timeFrame: Up to twelve weeks
measure: Hospital Anxiety and Depression Scale (HADS)
timeFrame: Up to twelve weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Jaén
country: Spain
facility: Miguel Ángel Fernández Sevilla
Study officials:
References: